Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
Pengfei Xu(Southern Medical University), Chengfei Liu(UC Davis Comprehensive Cancer Center)
Cited by 64
Related Papers
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2
|Journal of Experimental & Clinical Cancer Research|2019|59
Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models
|Pharmacological Research|2023|20
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer
|Oncogene|2023|18